Pricing Log in Create free account
Saturday 17 October 2026 Export CRDF’s income statement to Excel — free account

Cardiff Oncology, Inc.

CRDF Healthcare Biotechnology

Cardiff Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $593,000.00, down 13.2% from fiscal 2024. In the quarter to June 2026, revenue fell 14.1%, EPS grew 33.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.91 0.06 −6.19%
Market cap
$75.5M
P/E
0.0×
Fwd P/E
−2.2×
Dividend yield
—
F-score
2/9
Altman Z
−4.65
Beneish M
−4.02
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.12
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — 2 2 — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 75.54
Revenue 0.51
Net Income (40.05)
Free Cash Flow (40.94)
Net Debt (34.52)
Current Ratio 3.30 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (2.24) (negative: loss-making)
P/S ratio 122.52 (above 10: high)
P/B ratio 2.35
Past 5Y EPS Growth —
This Y EPS Growth 16.31% (at or above 15%: strong)
Next Y EPS Growth (5.38%) (below 0%: weak)
Next Y revenue growth (50.24%) (below 0%: weak)
Next 5Y EPS Growth (8.14%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 57.3×, against a ten-year median of 71.4×; over the ten years it ranged from −194× in 2022 to 1,593× in 2020.
P/S against its own 10 years 32.29%
10-year low 10-year high
P/B against its own 10 years 55.88%
10-year low 10-year high
EV/Sales against its own 10 years 33.15%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 75 92 58 35
Receivables 0 1 0 0
Inventory — — — —
Other — — — —
77 95 60 36
2023 2024 2025 Q'26
Payables 2 5 8 4
ST’ Debt — — — —
Other — — — —
10 13 16 11

Compound Annual Growth %

10y 5y 3y
Sales 6.61% 10.13% 15.39%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (0.70%) (18.75%) (24.71%)

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 1
’24 0 0 0 0 1
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 0 0 0 0 0
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (12) — — —
’25 (13) (8) (11) (6) (38)
’24 (8) (9) (10) (10) (38)
’23 (9) (7) (8) (7) (31)
’22 (10) (7) (7) (9) (34)
’21 (6) (4) (5) (7) (23)
’20 (3) (4) (4) (5) (16)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (12) — — —
’25 (13) (8) (11) (6) (38)
’24 (8) (9) (10) (10) (38)
’23 (9) (7) (8) (7) (31)
’22 (10) (7) (8) (9) (35)
’21 (6) (4) (6) (7) (23)
’20 (3) (4) (4) (5) (17)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.18) (0.14) — — —
’25 (0.20) (0.21) (0.17) (0.11) (0.69)
’24 (0.22) (0.26) (0.25) (0.21) (0.95)
’23 (0.25) (0.25) (0.22) (0.21) (0.93)
’22 (0.25) (0.24) (0.20) (0.20) (0.89)
’21 (0.14) (0.17) (0.17) (0.23) (0.73)
’20 (0.41) (0.51) (0.19) (0.19) (1.08)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 128.16 17.28 3.00 0.88 0.70 4.88 1.13 0.94 1.44 1.90

Analyst estimates 2026–2028

Powerpack
High 498.96 172.80 34.56 9.65 25.50 19.78 7.32 2.79 6.42 4.99
People
People Employees 53 17 13 14 12 23 26 32 33 31
Revenue/emp, $m 0.01 0.03 0.03 0.02 0.03 0.02 0.01 0.02 0.02 0.02
Income, $m
Income, $m Revenue 0 1 0 0 0 0 0 0 1 1
Gross margin, % (354.08) (258.41) (57.92) 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (39) (25) (16) (16) (19) (28) (39) (41) (45) (46)
EBT margin, % (10,286.99) (4,928.12) (4,351.36) (6,710.63) (5,275.14) (7,880.50) (10,026.94) (8,492.01) (6,651.68) (7,732.04)
Net income (39) (25) (16) (16) (19) (28) (39) (41) (45) (46)
Depreciation 2 1 1 0 0 2 1 (1) 0 0
Per share, $
Per share, $ Revenue 0.91 1.05 0.16 0.04 0.02 0.01 0.01 0.01 0.01 0.01
Earnings (93.62) (51.85) (8.26) (2.80) (1.08) (0.73) (0.89) (0.93) (0.95) (0.69)
Cash flow (74.08) (48.30) (5.66) (2.22) (0.78) (0.59) (0.78) (0.69) (0.79) (0.57)
Capex (1.97) (0.21) 0.01 (0.01) (0.01) (0.01) (0.02) (0.01) 0.00 0.00
Free cash flow (76.05) (48.51) (5.65) (2.23) (0.79) (0.60) (0.80) (0.70) (0.79) (0.57)
Book value 47.18 13.50 4.33 1.22 6.14 3.60 2.44 1.56 1.74 0.68
Shares, m 0 0 2 6 21 39 44 45 48 67
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 162.28 21.29 32.21 42.15 1,026.07 653.40 167.17 140.07 302.78 316.73
P/B 3.13 1.65 1.21 1.41 2.93 1.67 0.61 0.98 2.49 4.14
EV/Sales 106.24 32.78 38.61 8.85 672.05 265.07 (101.89) (10.36) 170.52 220.79
EV/FCF (1.27) (0.71) (1.11) (0.16) (14.83) (4.06) 1.13 0.16 (3.08) (3.45)
Cash, $m
Cash, $m Operating cash flow (31) (23) (13) (13) (16) (23) (34) (31) (38) (38)
Capex (1) 0 0 0 0 0 (1) (1) 0 0
Free cash flow (32) (23) (13) (13) (17) (23) (35) (31) (38) (38)
Balance, $m
Balance, $m Working capital 31 6 10 7 127 140 103 67 82 44
Total debt 17 1 — 2 1 3 3 — — —
Net debt (21) (7) (11) (10) (131) (141) (105) (75) (92) (58)
Shareholders’ equity 20 7 10 7 128 140 106 70 83 45
Returns, %
Returns, % ROA (67.99) (88.67) (145.55) (122.58) (30.58) (19.92) (29.15) (41.92) (50.84) (57.68)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (2,317.73) 0.00 0.00 0.00
ROE (114.59) (189.78) (232.13) (192.08) (33.36) (21.09) (31.39) (47.10) (59.54) (71.49)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Cardiff Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PMN Promis Neurosciences $78.0M — (loss-making) — 0.00% n/m −169.46% (below 0%: shrinking) 0.00% 0.00% Compare
PTHS Pelthos Therapeutics Inc. $77.6M — (loss-making) — (loss-making) — n/m −1,614.99% (below 0%: shrinking) 76.86% (111.02%) Compare
TELO Telomir Pharmaceuticals, Inc. $77.3M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
NTRB Nutriband Inc. $76.2M — (loss-making) 4.6× −29.72% (below 0%: shrinking) n/m +55.46% (above 0%: growing) 41.58% (203.57%) Compare
CRDF Cardiff Oncology, Inc. $75.5M — (loss-making) — (loss-making) −14.05% (below 0%: shrinking) n/m −41.36% (below 0%: shrinking) 100.00% (9,245.19%)
ACRV Acrivon Therapeutics, Inc. $75.4M — (loss-making) — — n/m +12.59% (above 0%: growing) 0.00% 0.00% Compare
OKYO OKYO Pharma Limited Sponsored ADR $75.1M — (loss-making) — — n/m +37.39% (above 0%: growing) 0.00% — Compare
PDSB PDS Biotechnology Corporation $72.8M — (loss-making) — — n/m +69.32% (above 0%: growing) 0.00% 0.00% Compare
HRTX Heron Therapeutics, Inc. $71.5M — (loss-making) — (loss-making) +1.25% (above 0%: growing) n/m +78.75% (above 0%: growing) 69.28% (5.43%) Compare
Median of peers $75.8M — — 0.00% — +24.99% 0.00% 0.00%

All 614 Biotechnology stocks →

Cardiff Oncology, Inc. (CRDF) key facts

  • Concern: Cardiff Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $593,000.00, down 13.2% from fiscal 2024.
  • Cardiff Oncology, Inc. (CRDF) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CRDF traded at $0.91, a market capitalization of $75.5 million.
  • Return on equity was −71.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −4.65 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Cardiff Oncology, Inc. (CRDF) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CRDF · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com